30.6 C
Vientiane
Sunday, June 22, 2025
spot_img
Home Blog Page 1090

Argon Medical Expands Oncology Product Offering with Acquisition of the SeQure® and DraKon™ Microcatheters

PLANO, Texas, Jan. 14, 2025 /PRNewswire/ — Argon Medical, a leading provider of medical device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology procedures, announces the acquisition of certain assets of Accurate Medical Therapeutics, Ltd., the manufacturer and distributor of the SeQure® and DraKon™ microcatheters, from Guerbet SA, a global leader in medical imaging. The addition of the SeQure and Drakon microcatheters to Argon’s portfolio extends the company’s oncology offering to include therapeutic devices and accessories. Argon is already well established in diagnostic oncology through its vast portfolio of biopsy devices.

Microcatheters such as SeQure and DraKon are commonly used by physicians to conduct interventional procedures in which therapeutic agents or devices are introduced into the small vessels delivering blood to a tumor or abnormality. As such, physicians often select a microcatheter for a procedure based on the catheter’s ability to navigate to the target and its compatibility with therapeutic agents or devices. Both the SeQure and Drakon catheters earned a strong reputation for being easy to navigate and broadly compatible. Further, SeQure is the only reflux control microcatheter designed to create a fluid barrier that directs the flow of therapeutic agents and devices toward the intended target.

“A microcatheter can make or break a procedure,” said Dr. Neal Khurana, MD. “A well-designed microcatheter determines whether you achieve precise navigation, efficient delivery of embolic materials, and ultimately, optimal patient outcomes. The DraKon and SeQure microcatheters have become preferred tools in my practice due to their dependable trackability through tortuous vessels, the performance of their hydrophilic coating, and their ability to deliver contrast and embolics efficiently, even through the smallest catheter sizes.” Dr. Khurana is a leading interventional radiologist and co-founder of EmboPartners, a physician-run organization that specializes in minimally invasive vascular embolization procedures for improved patient care.

“Adding the SeQure and DraKon microcatheters to our existing product portfolio marks an important first step in expanding the products we offer interventional oncologists beyond diagnostic procedures and into therapeutic delivery,” said George Leondis, President & CEO, Argon Medical. “As we do so, we also expand the ways in which we can improve the lives of patients and caregivers through the delivery of best-in-class medical devices and superior service, in alignment with our company mission.”

Following the close of this acquisition, Argon will transition manufacturing of the SeQure and DraKon catheters to the company’s primary manufacturing facility in Athens, Texas. Once complete, Argon intends to re-commercialize both microcatheters in all markets where they were sold previously and evaluate new opportunities to supply these products to new markets.

About Argon Medical

Since its founding in 1972, Argon Medical Devices has earned a reputation for delivering innovative products, superior service, and exceptional value for Interventional Radiologists, Vascular Surgeons, and Interventional Cardiologists worldwide. Argon is proud to have over 1,200 employees, and manufacture products in the United States in Texas, Illinois, New York, and Wisconsin. Argon brands are well-known globally, highlighted by the Option™ ELITE IVC Filter, the CLEANER™ Rotational Thrombectomy System, the BioPince™ Ultra Full-Core Biopsy Instrument, and SKATER™ Percutaneous Drainage Catheters. By utilizing a well-established sales and marketing infrastructure, Argon serves its global customers through a direct sales organization, and long-standing relationships with medical device distributors and strategic partners.

Korea’s Leading Indie Beauty Brand d’Alba, Reaches New Heights Globally with 210% Overseas Sales Surge

SEOUL, South Korea, Jan. 14, 2025 /PRNewswire/ — Premium vegan beauty brand d’Alba has achieved significant growth in its overseas sales, rising  to approximately KRW 150 billion won (USD 100 million) in 2024 – which is a 210% growth compared to the previous year. With this growth, d’Alba’s international market revenue now accounts for 45% of its total revenue.

Its global growth came from its flagship product, the White Truffle First Spray Serum, alongside Waterful Sunscreen and Double cream. d’Alba’s consistent performance across diverse global markets including Japan, ASEAN countries, US, EU, and Russia highlights its strong customer base and successful penetration into the international beauty scene.

d’Alba had been generating most of its sales from the Korean market until 2023. The First Spray Serum initially gained traction in Korea as the “Flight Attendant Mist” getting widely known with its innovative formulation based on premium ingredients like White Truffles with the convenience of a spray. With this product, the brand gained its leading position in the domestic market with notable references in the major beauty channels – top 3 at Olive Young, 1st rank in the Naver Shopping Beauty Category, and 1st rank in Coupang’s Suncare/Essence/Ampoule Category.

Previously recognized primarily for its strong domestic performance, d’Alba has swiftly transitioned to the global stage. In 2024, d’Alba’s overseas revenue climbed significantly to USD 110 mn from USD 35 mn in 2023. Now d’Alba’s global sales accounts for 45% of total sales whereas it was about 22% in 2023.

An industry expert commented, “While many K-beauty brands’ revenue rely on specific markets such as China, U.S, or Japan, d’Alba’s evenly distributed growth across Europe, Japan, North America, and ASEAN is a rarity. This positions them uniquely in the competitive landscape.”

Looking ahead, the brand is optimistic about the continued expansion, stating “These global markets are still at the early stage. We’re receiving many inquiries from large retail platforms worldwide. Our focus on channel expansion and the new products such as beauty devices will drive further growth.”

IFF Pharma Solutions Wins Pharmaceutical Technology Excellence Award

Recognized for brand leadership with its “Timing is Everything” controlled release platform for oral drug delivery.

NEW YORK, Jan. 14, 2025 /PRNewswire/ — IFF (NYSE: IFF) Pharma Solutions, a global leader in polymer innovations, announced today that it has won the 2024 Pharmaceutical Technology Excellence Awards’ Brand Leadership category for its “Timing is Everything” campaign. The campaign features IFF’s newly designed controlled release platform, which provides customers with solutions at every turn.

This award recognizes “Timing is Everything” campaign for its strategic marketing tactics, creativity and leadership. The campaign focuses on building an integrated thought leadership platform for controlled release through storylines and cohesive branding. It includes a three-pronged approach with a social media teaser countdown, video and microsite.

“We are honored to receive this esteemed recognition for our ‘Timing is Everything’ campaign that highlights our controlled release portfolio,” said Lisa M. Miree-Luke, global communications director, IFF Pharma Solutions. “This award is a testament to our trailblazing products and the passionate teams behind them. METHOCEL™─Pioneering Then, Innovating Now; ETHOCEL™─Proven Time After Time and POLYOX™─Versatile Across Complex and Unique Applications, they are not just taglines but promises we stand by. We are committed to driving innovation, quality and helping to enable our customers’ successes.”

The “Timing is Everything” campaign elevates brand awareness and culminates in the creation of a best-in-class dedicated thought leadership platform for controlled release polymers in the excipients industry. The platform educates visitors about pharmaceutical formulations that benefit patients and the importance of controlled release of active ingredients through comprehensive materials such as white papers, webinars and articles.

The Pharmaceutical Technology Excellence Awards honors the most significant achievements and innovations in the pharmaceutical industry. Powered by GlobalData’s business intelligence, the awards recognize the people and companies leading change and shaping the future of the industry.

###

Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.comLinkedInInstagram and Facebook.

©2025 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with TM, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.

Contact:
Emily Kaufman
Global Communications Specialist
+1 9086705691
Emily.Kaufman@iff.com

ImmunoForge Receives IND Approval for Phase 2 Clinical Trial of ‘Pemziviptadil’ for DMD Cardiomyopathy Treatment from FDA, and KF1601, a chronic myeloid leukemia treatment, phase 1 clinical trial IND approved by MFDS

SEOUL, South Korea, Jan. 14, 2025 /PRNewswire/ — ImmunoForge announced that it has received approval for the Phase 2 clinical trial IND for ‘Pemziviptadil (development code name PF1804),’ a treatment for DMD (Duchenne Muscular Dystrophy) cardiomyopathy, from the U.S. Food and Drug Administration (FDA).

Pemziviptadil is a once-weekly DMD cardiomyopathy drug developed based on ImmunForge’s long-acting drug platform, the ELP Platform (Elastin Like Polypeptide Platform). Pemziviptadil is a vasoactive intestinal peptide (VIP) that selectively acts on the vasoactive intestinal peptide receptor 2 (VPAC2) to increase both cardiac contraction and relaxation, thereby improving cardiac function.

Vasoactive intestinal peptide has been difficult to develop as a therapeutic agent because its half-life in the body is less than 1 minute. However, ImmunoForge has developed a first-in-class new drug with an increased half-life of 60 hours by combining it with the ELP platform, a long-acting drug platform, and selectively acting on vasoactive intestinal peptide receptor 2 (VPAC2) while avoiding gastrointestinal side effects such as diarrhea of vasoactive intestinal peptide receptor 1 (VPAC1). The effect of suppressing cardiac dysfunction was confirmed in a non-clinical MDX mouse model conducted in the United States, and following this approval for phase 2 clinical trials, phase 2 clinical trials are scheduled to be conducted in the United States and Korea.

The most common cause of death for DMD (Duchenne Muscular Dystrophy) patients was respiratory failure, but due to improvements in respiratory care and other treatments, cardiomyopathy is emerging as the main cause of death for these patients rather than respiratory failure. Deficiency of cardiac dystrophin protein impairs calcium channel function, which plays an important role in muscle contraction, leading to an increase in intracellular calcium, which in turn increases protein-degrading enzymes and causes protein degradation. This leads to muscle fiber and cell necrosis, and most patients develop cardiomyopathy in their 30s. It is estimated that there are currently 500,000 DMD patients worldwide, and since more than 80% of DMD patients die from this cardiomyopathy, if proper treatments are developed in the future, the DMD cardiomyopathy treatment market is expected to reach tens of trillions. Current treatments, such as beta-blockers and calcium channel blockers, can reduce heart rate and myocardial contractility, but there is no treatment for long-term and fundamental myocardial improvement.

ImmunoForge’s co-CEOs Sung-Min Ahn and Kiho Chang said, “Based on this US FDA approval for phase 2 clinical trials, we expect to confirm the therapeutic effect of Pemziviptadil in phase 2 clinical trials and thereby secure an unrivaled position in the DMD cardiomyopathy treatment market, where there is currently no appropriate treatment.” He added, “As many overseas companies are currently showing interest in Pemziviptadil, we will actively pursue collaborative models such as joint development and technology transfer.”

Pemziviptadil is a new drug that is expected to be effective not only for DMD cardiomyopathy but also for other heart diseases such as heart failure (HF) and pulmonary arterial hypertension (PAH) through nonclinical studies and various phase 1 clinical trials and has received orphan drug designation (ODD) for pulmonary arterial hypertension in addition to DMD cardiomyopathy from the US FDA. Meanwhile, Pemziviptadil was selected for a strategic technology-type international joint technology development project by the Korea Institute for Advancement of Technology in 2023 and is receiving a total of KRW 3 billion in support until 2026.

Around the same time, ImmunoForge also announced that it has received approval for the phase 1 clinical trial IND for ‘KF1601 (development code name)’, a treatment for Chronic Myelogenous Leukemia (CML), from the Korea Ministry of Food and Drug Safety.

KF1601 is a novel synthetic oral TKI targeted therapy that inhibits BCR::ABL1. It effectively inhibits the T315I mutation during the nonclinical development process and exhibits excellent safety and tolerability. It is expected to be a treatment that can be used more universally than existing CML treatments, and it is expected to contribute to managing chronic myeloid leukemia as a chronic disease that can overcome resistance by replacing existing treatments.

Chronic myeloid leukemia is a blood cancer that is caused by the excessive proliferation of myeloid cells and inhibition of apoptosis of BCR::ABL1 tyrosine kinase, which is expressed as a result of the Philadelphia chromosome (Philadelphia chromosome (Ph) abnormality caused by the fusion between the Abelson (Abl) tyrosine kinase gene on chromosome 9 and the Breakpoint Cluster Region (Bcr) gene on chromosome 22, a chimeric oncogene. CML accounts for approximately 30% of the total adult leukemia incidence, and it presents differently depending on age, gender, and region, and is reported to occur in approximately 0.4 to 1.75 cases per 100,000 people per year. Especially, ImmunoForge’s KF1601 has the effect of simultaneously inhibiting FLT3 in the Blast Phase patient group, and this effect was announced at the Molecular Cancer Society last year, so it is expected to be a differentiating point for KF1601 in CML drugs.

ImmunoForge’s co-CEOs Sung-min Ahn and Kiho Chang said, “Based on this Phase 1 IND approval, we plan to confirm the safety of KF1601 in the Phase 1 clinical trial and develop it targeting the global market including the US and Europe in addition to Korea.” They added, “Based on the development results, we plan to participate in academic conferences and global partnering events and actively pursue technology transfers with global pharmaceutical companies.” ImmunoForge is currently in discussions with several domestic and foreign companies.

Meanwhile, ImmunoForge is currently in the process of Series C funding and plans to apply for a technology assessment by the end of this year and pursue a KOSDAQ listing next year.

DJI Launches All-in-One Vlog Camera Drone with DJI Flip

New DJI Flip is DJI’s first drone to feature foldable, full-coverage propeller guards for ultimate flight safety

SHENZHEN, China, Jan. 14, 2025 /PRNewswire/ — DJI, the global leader in civilian drones and creative camera technology, today announces DJI Flip, a new series of all-in-one vlog camera drones. At less than 249g[1], this compact drone features foldable full-coverage propeller guards[1], ensuring ultra-safe and reliable flying. Photographers can capture impressive 48MP photos and 4K videos with the drone’s 1/1.3-inch CMOS sensor with one tap of a button. Being fully equipped with comprehensive protection at all times, even beginner pilots can confidently navigate the skies with DJI Flip.

DJI Launches All-in-One Vlog Camera Drone with DJI Flip

“Building on the success of our consumer camera drones, we are introducing DJI Flip to combine the simplicity of the DJI Neo with the stunning photo capabilities of the DJI Mini to make both aerial photography and close-up portraits accessible for everyone,” said Ferdinand Wolf, Product Experience Director at DJI. “DJI Flip combines creative tools like AI subject tracking[1] and intelligent shooting modes[1] with safety features like our latest foldable propeller guards and automatic braking, making it easier than ever for people to capture stunning aerial footage no matter their level of photography or drone expertise.”

Ultra Safe and Reliable Flights

DJI Flip makes flying safe and reliable thanks to its foldable, full-coverage guard that wraps the propellers to avoid injury or damage to the drone. Made of lightweight and strong carbon fiber string, the guard’s support structure is only 1/60 the weight of guards made with traditional polycarbonate material while maintaining the same stiffness and durability to ensure safe flights.

Intelligent One-Tap Aerial Photography

DJI Flip makes flying simple, requiring no special training in most countries and regions. This palm-sized drone is lightweight and compact, making it an ideal travel companion for capturing any adventure. Whether hiking through forests or climbing steep peaks, DJI Flip makes flying simple. With one tap of the mode button, photographers can select from six intelligent shooting modes to capture impressive footage. AI Subject Tracking[1] can also be enabled to keep a subject in the frame. Six intelligent shooting modes include Dronie, Circle, Rocket, Spotlight, Helix, and Boomerang.

Strong Camera with Smart Enhancements 

DJI Flip can capture high-dynamic 48MP photos with more highlight and shadow details. The camera is powered by a 1/1.3-inch CMOS sensor featuring Dual Native ISO Fusion, f/1.7 aperture, and 2.4μm 4-in-1 pixels. It can also capture photos with up to 4x zoom. Intricate details can be preserved with next-gen SmartPhoto[1], which combines HDR imaging, scene recognition, and more for images that pop.

DJI Flip records HDR video at 4K resolution and 60 frames per second, promising footage with true-to-life quality. It also supports slow-motion recording at 4K/100fps and 10-bit D-Log M color mode. A 4:3-aspect-ratio CMOS sensor provides enough space for vertical crops while maintaining a 2.7k resolution, optimized for smartphone viewing and social media without any cropping needed.

DJI’s intelligent shooting features easily produce professional-grade work:

  • MasterShots: Allows DJI Flip to automatically perform diverse camera movements, shooting multiple clips and editing them with music, cuts, and effects for fast and simplified cinematic footage.
  • Hyperlapse: Select from four options, including Free, Circle, Course Lock, and Waypoint to capture timelapse footage at up to 4K horizontally or 2.7K vertically.
  • FocusTrack: Find creative ways to follow your subject with FocusTrack. The suite includes ActiveTrack 4.0, Spotlight 2.0, and Point of Interest 3.0, three powerful storytelling tools.
  • Panorama: Supports shooting 180°, Wide Angle, Vertical, and Sphere panoramic photos to capture magnificent landscapes.

Other Standout Features

  • 31-minute Max Flight Time[1]: DJI Flip’s Intelligent Flight Battery delivers up to 31 minutes of flight time, ensuring seamless creation without battery concerns.
  • Automatic Braking[1]: DJI Flip’s 3D Infrared Sensing System support automatic braking for enhanced safety, even at night.
  • Next Level Video Transmission: When paired with the DJI RC-N3 or RC 2 remote controller, DJI O4 video transmission supports up to 13 km[1] of 1080p/60fps video transmission and has excellent anti-interference capabilities, allowing you to explore vast landscapes with clarity.
  • Fast Charging and Data Transfers[1]: The DJI Flip Parallel Charging Hub charges two batteries simultaneously[1], significantly reducing charging time. With the DJI Fly app, footage can be transferred at speeds up to 30MB/s.
  • Fly With or Without Remote Controller: The DJI Flip can be operated with the DJI RC-N3 or RC 2 remote controllers. It can also operate with the DJI Fly app or Voice Control[1] for hands-free flying. When connected to your phone, it can capture audio and intelligently reduce noise, automatically filtering out propeller noise

Price and Availability

DJI Flip is available to order from store.dji.com and authorized retail partners, with shipping starting today, in the following configurations:

  • DJI Flip retails for $439
  • DJI Flip (DJI RC 2) retails for $639
  • DJI Flip Fly More Combo (DJI RC 2) retails for $779

DJI Care Refresh

DJI Care Refresh, the comprehensive protection plan for DJI products, is now available for DJI Flip. The replacement service covers accidental damage, including flyaway, collisions and water damage. For a small additional charge, you can have your damaged product replaced if an accident occurs.

DJI Care Refresh (1-Year Plan) includes up to two replacements in one year. DJI Care Refresh (2-Year Plan) includes up to four replacements in two years. Other services of DJI Care Refresh include official Warranty and free shipping. For a full list of details, please visit: https://www.dji.com/support/service/djicare-refresh.

For more information, please refer to https://www.dji.com/flip.

[1] All data was tested in controlled conditions. Actual experience may vary. For more details, please refer to the product page on the official DJI website.

Triller Downloads Skyrocket Ahead of TikTok Ban

LOS ANGELES, Jan. 14, 2025 /PRNewswire/ — Triller, a creator-focused social media platform, has jumped more than 100 spots on the Apple App download chart as users look for a new home ahead of the TikTok ban, set to go into effect January 19, 2025.

Under the leadership of Sean Kim, a former TikTok executive who took the helm as CEO of the Triller App in November, the number of daily new users has doubled. User growth is expected to continue to accelerate.

Triller’s savemytiktoks.com utilizes Triller’s Amplify.ai technology, enabling creators to seamlessly migrate their content directly to their Triller profile.

“Having navigated the dynamic landscapes of both TikTok and Amazon Prime, I recognize the vital importance of creator empowerment, community, and commerce.” said Sean Kim, CEO of the Triller App. “The response to our ‘Save my TikToks’ campaign has been overwhelming, highlighting the great need in the industry for an app that supports creators and their work. At Triller, we are building a revolutionary platform that truly puts creators first. The next generation of the app is about giving creators the tools, ownership, control, freedom, and monetization opportunities they’ve always deserved.”

For more details, please visit savemytiktoks.com.

Triller Corp is owned by Triller Group Inc.

About Triller Group Inc.

Triller Group is a US-based company that operates two main businesses: the newly merged US- based social media operations (Triller Corp.), and the legacy operations of the Company in Hong Kong (“AGBA”).

Triller Corp. is a next generation, AI-powered, social media and live-streaming event platform for creators. Pairing music culture with sports, fashion, entertainment, and influencers through a 360-degree view of content and technology, Triller Corp. uses proprietary AI technology to push and track content virally to affiliated and non-affiliated sites and networks, enabling them to reach millions of additional users. Triller Corp. additionally owns Triller Sports, Bare-Knuckle Fighting Championship (BKFC); Amplify.ai, a leading machine-learning, AI platform; and TrillerTV, a premier global PPV, AVOD, and SVOD streaming service. For more information, visit www.triller.co.

Established in 1993, AGBA is a leading, multi-channel business platform that offers a broad set of financial services and healthcare products to consumers through a tech-led ecosystem, enabling clients to unlock the choices that best suit their needs. The Group is organized into four market- leading businesses: Platform Business, Distribution Business, Healthcare Business, and Fintech Business. For more information, please visit www.agba.com.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s goals and strategies; the Company’s future business development; product and service demand and acceptance; changes in technology; economic conditions; the outcome of any legal proceedings that may be instituted against us following the consummation of the business combination; expectations regarding our strategies and future financial performance, including its future business plans or objectives, prospective performance and opportunities and competitors, revenues, products, pricing, operating expenses, market trends, liquidity, cash flows and uses of cash, capital expenditures, and our ability to invest in growth initiatives and pursue acquisition opportunities; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in Hong Kong and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC, the length and severity of the recent coronavirus outbreak, including its impacts across our business and operations. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.

Investor & Media Relations:

Bethany Lai
ir@triller.co

Breanne Fritcher
triller@wachsman.com

Cognex Strengthens Market Leadership in Industrial Barcode Reading with Two New AI-Powered Products

DataMan 290 and 390 barcode readers, backed by industry-leading customer support, deliver unmatched reliability and ease of use

NATICK, Mass., Jan. 14, 2025 /PRNewswire/ — Cognex Corporation (NASDAQ: CGNX), the leader in industrial machine vision, today announced the launch of the DataMan® 290 and 390 barcode readers. Thanks to innovative AI technology, these readers deliver reliable decoding performance across a broad range of manufacturing applications. In addition, by making setup and deployment easy and intuitive, Cognex has given more users than ever the power to streamline barcode scanning processes and increase operational efficiency.

The AI-powered DataMan 290 and 390 barcode readers are shown side by side.

“The DataMan 290 outperformed other competitive solutions we tested, successfully reading codes that others couldn’t,” said Peter Laurinčík, CEO, MTS – Modern Technology Systems. “This reliability, plus an intuitive design, will transform our barcode reading operations, allowing us to increase productivity and throughput. The comprehensive support offered by Cognex, from setup and training to deployment and runtime, ensures smooth performance every step of the way.”

The DataMan 290 and 390 provide a full set of features to let users get started quickly and efficiently handle a wide range of applications:

  • Advanced AI capabilities enable users to reliably read codes with a single click, simplifying setup and maintenance while reducing downtime, even for non-technical users.
  • Effortless handling of varied code types and symbologies, including damaged or low-quality codes, and high read rates even in low-visibility environments thanks to an integrated all-in-one light.
  • A user-friendly web interface with guided setup allows even non-technical users to go from unboxing to scanning in mere minutes.

Beyond advanced technology, DataMan 290 and 390 barcode readers are backed by Cognex Customer Success, industry-leading support that works the way you want, from self-service resources to a global network of experts. The best technology and tailored guidance enable users to easily plan, deploy, and expand their vision project.

The DataMan 290 solves most barcode reading applications out of the box, while the DataMan 390 delivers higher resolution for the most complex applications, offering a complete range of solutions to meet code scanning requirements. These readers, along with Cognex Customer Success, reflect the company’s commitment to deliver best-in-class customer experience, while driving innovation in industrial barcode reading. For more information, visit cognex.com/dataman-290 or call 1-855-4-COGNEX.

About Cognex Corporation
Cognex Corporation invents and commercializes technologies that address some of the most critical manufacturing and distribution challenges. We are a leading global provider of machine vision products and solutions that improve efficiency and quality in high-growth-potential businesses across attractive industrial end markets. Our solutions blend physical products and software to capture and analyze visual information, allowing for the automation of manufacturing and distribution tasks for customers worldwide. Machine vision products are used to automate the manufacturing or distribution and tracking of discrete items, such as mobile phones, electric vehicle batteries and e-commerce packages, by locating, identifying, inspecting, and measuring them. Machine vision is important for applications in which human vision is inadequate to meet requirements for size, accuracy, or speed, or in instances where substantial cost savings or quality improvements are maintained.

Cognex is the world’s leader in the machine vision industry, having shipped more than 4.5 million image-based products, representing over $11 billion in cumulative revenue, since the company’s founding in 1981. Headquartered in Natick, Massachusetts, USA, Cognex has offices and distributors located throughout the Americas, Europe, and Asia. For details, visit cognex.com.

IR Contact
Nathan McCurren
Head of Investor Relations and Treasurer
Cognex Corporation
ir@cognex.com

Media Contact
Jeremy Sacco
Senior Manager, Global Content Marketing
Cognex Corporation
pr@cognex.com

RuggON Launches VIKING II: Transforming Fleet Management with Unmatched Technology and Flexibility

Powered by Android 14 and Qualcomm® Snapdragon™ 6490 Octa-Core Processor, Engineered for Demanding Fleet Applications

TAIPEI, Jan. 14, 2025 /PRNewswire/ — RuggON Corporation proudly introduces the VIKING II, a groundbreaking fleet management device designed to tackle the toughest industrial challenges. Combining cutting-edge technology with exceptional durability, the VIKING II raises the bar for operational efficiency in logistics, mining, construction, and public safety. Designed with adaptability and performance in mind, it empowers businesses to excel in even the harshest environments.

Powered by Android 14 and Qualcomm® Snapdragon™ 6490 Octa-Core Processor, Engineered for Demanding Fleet Applications

At its core, the VIKING II is powered by the Qualcomm® Snapdragon™ 6490 Octa-Core Processor, delivering unparalleled performance for complex, data-heavy tasks. Combined with Android 14 and Google Mobile Services (GMS) certification, the device offers a seamless user experience with access to a vast ecosystem of applications. Whether monitoring vehicle health, managing data, or running custom fleet management tools, the VIKING II ensures dependable performance and unparalleled flexibility.

Engineered for extreme conditions, the IP65-rated VIKING II pairs rugged design with advanced connectivity options like 5G and SATCOM, ensuring uninterrupted communication and real-time data transfer, even in remote or off-grid areas. Multi-GNSS support, equipped with Dead Reckoning and RTK technology, enables precise location tracking in GPS-denied environments, such as tunnels or urban canyons.

By integrating critical tools into a single device, the VIKING II simplifies fleet operations and reduces costs. It features advanced functionalities like TPMS (Tire Pressure Monitoring System), NFC capabilities, remote door control, and a secondary display, streamlining workflows and enhancing delivery efficiency. Real-time tracking boosts on-time performance, while TPMS prolongs tire life, promoting safety and sustainability.

For additional information about VIKING II, please visit https://www.ruggon.com/en/product/mobile-computers/VIKINGII or follow us on Ubiqconn Technology.

About RuggON

RuggON Corp., a subsidiary of Ubiqconn Technology, is a leading manufacturer of rugged mobile computing solutions. Combining Ubiqconn’s advanced technology to drive innovation and expand in the Mobile Industrial (IioT) market, RuggON leverages decades of expertise to improve mobile productivity in harsh environments. A committed engineering team delivers devices of exceptional value and quality that enhance user experience. The company understands the diverse demands of industries to provide tailored, efficient solutions. RuggON is dedicated to higher standards for customer satisfaction and prides itself on offering endless possibilities to meet tomorrow’s needs. For more information, visit http://www.ruggon.com or follow us on LinkedIn.